淋巴结阳性宫颈癌根治性放化疗后残留淋巴结状态的预后意义
回顾性分析117例淋巴结阳性宫颈癌患者,2006至2016年在本机构接受根治性放化疗,中位随访41个月。放化疗后3个月残留淋巴结31例(26.5%),多因素分析显示残留淋巴结与更差总生存相关(HR 3.04,95%CI 1.43-6.44,p=0.004),5年生存预测ROC的AUC为0.72。
要点
- 放化疗后3个月残留淋巴结见于31/117例(26.5%),残留原发肿瘤见于30例(25.6%)。
- 残留淋巴结与更差总生存相关,多因素分析HR 3.04(95%CI 1.43-6.44,p=0.004)。
- 5年时间依赖ROC分析中,残留淋巴结预测生存的AUC值为0.72。
核心结论
- 淋巴结阳性宫颈癌患者根治性放化疗后存在残留淋巴结与更差生存相关。
研究设计与样本
- 回顾性分析纳入117例淋巴结阳性宫颈癌患者,均在本机构接受根治性放化疗,时间范围为2006年至2016年。
- 中位随访期为41个月(范围6-128个月)。
- 阳性淋巴结判定标准为治疗前磁共振成像(MRI)/计算机断层扫描(CT)上最大短轴直径≥8mm。
- 放化疗完成后3个月行盆腔MRI复查。
- 残留原发肿瘤定义为临床检查和/或MRI发现的任何残留病灶;残留淋巴结定义为治疗后MRI/CT上短轴直径≥8mm的任何淋巴结。
主要发现
- 放化疗后3个月随访时,观察到残留原发肿瘤30例(25.6%),残留淋巴结31例(26.5%)。
- 多因素分析显示,残留淋巴结的存在与更差总生存相关(风险比3.04;95%置信区间1.43-6.44;p=0.004)。
- 在生存预测的5年时间依赖ROC分析中,残留淋巴结的存在显示AUC值为0.72。
关键数值与推荐
- 阳性淋巴结判定标准:治疗前MRI/CT上最大短轴直径≥8mm。
- 残留淋巴结判定标准:治疗后MRI/CT上短轴直径≥8mm。
- 残留淋巴结与更差总生存相关:HR 3.04(95%CI 1.43-6.44,p=0.004)。
- 残留淋巴结预测5年生存的AUC值为0.72。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Lymph node involvement is an important prognostic factor in patients with cervical cancer. However, the prognostic significance of lymph node response to chemoradiotherapy remains unclear. We retrospectively analyzed the relationship between residual lymph node status after definitive chemoradiotherapy and survival. METHODS: We enrolled 117 patients with node-positive cervical cancer. All patients were treated with definitive chemoradiotherapy in our institution, from 2006 to 2016. The median follow-up period was 41months (range, 6-128months). The criterion for a positive lymph node was defined as a maximum short axis diameter of ≥8mm on pretreatment magnetic resonance imaging (MRI)/computed tomography (CT) scans. Posttreatment pelvic MRI was obtained 3months after the completion of chemoradiotherapy. Residual primary tumor was defined as any residual lesion identified upon clinical examination and/or MRI. Residual lymph node was defined as any lymph node with a short axis diameter of ≥8mm posttreatment, according to MRI/CT. RESULTS: At follow-up, 3months after chemoradiotherapy, we observed residual primary tumor in 30 patients (25.6%), and residual lymph node in 31 patients (26.5%). The presence of residual lymph node was associated with worse overall survival according to multivariate analysis (hazard ratio, 3.04; 95% confidence interval, 1.43-6.44; p=0.004). In the 5-year time-dependent ROC analysis of survival prediction, the presence of residual lymph node showed an AUC value of 0.72. CONCLUSIONS: The presence of residual lymph node after chemoradiotherapy was associated with worse survival in patients with node-positive cervical cancer.
引用
- Park SH, Cheon H, Chong GO, et al. Prognostic significance of residual lymph node status after definitive chemoradiotherapy in patients with node-positive cervical cancer. Gynecol Oncol. 2018. PMID: 29329882. doi:10.1016/j.ygyno.2018.01.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。